Active Biotech AB Year-end report January - December 2017
February 15 2018 - 2:30AM
Fourth quarter in
brief
-
The primary clinical endpoint was not met in the
Phase II study (ARPEGGIO) with laquinimod in PPMS
-
Patent regarding tasquinimod for the treatment
of acute leukemia granted in Europe
-
The process to divest the company's property in
Lund is ongoing
-
On December 7, the company announced that
funding for the next 12 month period was not guaranteed. See
further below "Events after the end of the period" relating to a
new share issue
Other significant events during
the January-December period
-
Patent regarding tasquinimod for the treatment
of multiple myeloma (MM) granted in Europe
-
FDA granted orphan drug status for tasquinimod
for the treatment of MM.
-
The primary clinical endpoint in the Phase III
study of laquinimod in RRMS (CONCERTO) was not met. The secondary
endpoints were met in line with previous studies
-
Helén Tuvesson was appointed CEO of Active
Biotech
-
The first product patent in the SILC project was
granted in the US
-
The decision was taken to discontinue the
company's laboratory animal facility in Lund
-
The Phase II study of laquinimod in Huntington's
disease (LEGATO-HD) is ongoing. Results are expected in the second
half of 2018
-
The ANYARA project is proceeding, with planned
start of clinical studies in the second half of 2018
-
Out-licensing activities are continuing for the
tasquinimod, SILC and paquinimod projects
Events after the end of the
period
-
The Board of Directors proposes a new share
issue of approximately MSEK 48, with pre-emptive rights for the
shareholders. An extraordinary general meeting to be held on March
19, 2018
-
In connection with the new share issue, the
company has received a permanent waiver from its commitment to the
bank that finances the company's property in Lund that the
company's liquidity should never fall below MSEK 30
-
The company again has funding for the coming 12
month period
-
Patent application regarding tasquinimod for the
treatment of MM allowed in the US
-
Application for the second product patent in the
SILC project allowed in the US
Financial
summary
SEK M |
Oct.-Dec. |
Jan.-Dec. |
|
2017 |
2016 |
2017 |
2016 |
|
|
|
|
|
Net sales |
5.4 |
7.1 |
20.2 |
19.0 |
Operating loss |
*-58.4 |
-13.5 |
*-102.5 |
-55.1 |
Loss after tax |
*-60.1 |
-14.8 |
*-108.8 |
-59.6 |
Earnings per share (SEK) |
-0.62 |
-0.16 |
-1.12 |
-0.65 |
Cash and cash equivalents (at close
of period) |
|
|
25.2 |
77.7 |
|
|
|
|
|
|
*of which write down of
property SEK 50 M
For further
information, please contact:
Helén Tuvesson, CEO
Tel: +46 (0)46-19 21 56
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
|
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
|
The report is also available at
www.activebiotech.com.
Active Biotech AB Year-end report
January – December 2017
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024